Cholera Vaccination and Epidemiological Insights

Cholera remains a pressing global health threat, with outbreaks driven by environmental, infrastructural and socio-behavioural factors. Vaccination campaigns using killed whole-cell oral cholera vaccines have become central to both reactive outbreak control and proactive prevention in endemic settings. Recent advances integrate serological and genomic data to refine estimates of true infection burden, track multidrug-resistant strains and understand immunity dynamics following vaccination. Serological surveillance complements clinic-based reporting by revealing subclinical infections and age-specific exposure patterns, thereby informing the deployment of limited vaccine stocks. Meanwhile, genomic epidemiology has elucidated the spread of resistance plasmids among Vibrio cholerae lineages and the emergence of novel subclades driving major epidemic waves. Together, these developments underscore the importance of combining traditional epidemiological methods with molecular and immunological tools to optimise vaccination strategies, anticipate resurgence during seasonal transitions and target high-risk populations. Practical outcomes include refinements to dosing regimens, evidence of sustained single-dose protection in high-burden settings, and identification of correlates of protection beyond vibriocidal titres, all of which shape policies aimed at cholera elimination by 2030.

Research from Nature Portfolio

Recent studies have demonstrated that reliance on clinic-based surveillance alone can substantially underestimate Vibrio cholerae O1 infection rates in endemic communities. By integrating longitudinal serology with healthcare-seeking behaviour, researchers reconstructed transmission timelines revealing that fewer than one in a thousand infections are captured by standard reporting systems, with annual incidence exceeding 500 per 1,000 population in some age groups. Parallel genomic investigations have traced the emergence and dissemination of multidrug resistance, documenting the horizontal transfer of an incompatibility type C plasmid carrying a composite transposon among seventh pandemic El Tor lineages during the Yemen outbreak. Another genomic analysis of the 2022 Bangladesh surge identified a distinct subclade that acquired serotype-switching mutations and rapidly displaced previously dominant strains. These insights highlight the dynamic interplay between pathogen evolution and epidemiological patterns, emphasising the need for real-time molecular surveillance to guide vaccine deployment and antibiotic stewardship.

Cholera Vaccination and Epidemiological Insights publication trend

The graph below shows the total number of articles in cholera vaccination and epidemiological insights across all publications each year (not limited to Nature Index journals).

Technical terms

Oral cholera vaccine (OCV): An ingestible formulation containing killed Vibrio cholerae antigens designed to induce mucosal immunity and prevent cholera infection.

Serological surveillance: Monitoring of antibody levels in a population to estimate infection exposure that may not be captured by clinical reporting.

Seroconversion: The development of detectable specific antibodies in the blood following infection or vaccination, indicating an immune response.

Vibriocidal antibody titre: A measure of serum antibodies that kill V. cholerae in vitro, traditionally used as a correlate of protection.

Integrative and conjugative element (ICE): A mobile genetic element that can integrate into bacterial chromosomes and mediate horizontal gene transfer, including antibiotic resistance genes.

Multidrug resistance (MDR): The ability of a bacterial strain to withstand treatment by multiple antibiotic classes, often mediated by plasmids or transposons.

References

1. Clinical surveillance systems obscure the true cholera infection burden in an endemic region. Nature Medicine (2024).
2. Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen. Nature Microbiology (2023).
3. Genomic attributes of Vibrio cholerae O1 responsible for 2022 massive cholera outbreak in Bangladesh. Nature Communications (2023).
4. Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study. The Lancet Infectious Diseases (2024).
5. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. The Lancet Global Health (2024).
6. Predicting Vibrio cholerae infection and symptomatic disease: a systems serology study. The Lancet Microbe (2023).